Skip to main content
Log in

Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin

  • Combination Chemotherapy (II)
  • Advanced Urothelial Cancer, M-VAC Chemotherapy, Factors Affecting Response
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Attempts were made to identify factors related to the response of patients treated with intravenous methotrexate, vinblastine, Adriamycin, and cisplatin (M-VAC). The subjects consisted of 54 patients with advanced urothelial cancer whose histological type was transitional-cell carcinoma. The effects of various factors on the response were studied using univariate analysis and a multiple logistic regression model. The following factors were included in the anlayses: (1) age, (2) sex, (3) performance status (PS), (4) primary site, (5) histological grade, (6) T category, (7) N category, (8) M category, (9) tumor status, and (10) dose of drugs. In all, 9 patients achieved a complete response and 23 showed a partial response, for an overall response rate of 59% (95% confidence limits, 46%–72%). Univariate analysis revealed that the PS, M category, and dose of drugs were related to the response, and there was a significant correlation among these three factors. In the multiple logistic regression model, the absolute value oft was high for the M category. The presence of distant metastases is an important factor in predicting poor efficacy for the present regimen. The management of metastatic disease will be the subject of further study in the treatment of advanced urothelial cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Freiha F, Vries C de, Torti F (1988) Neoadjuvant and adjuvant chemotherapy of transitional cell carcinoma of the urothelium with cisplatin, methotrexate and vinblastine. World J Urol 6: 153

    Google Scholar 

  2. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap H-Y, Buzdar AU, Blumenschein GR (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1: 776

    Google Scholar 

  3. Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, Usui T (1990) Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 144: 662

    Google Scholar 

  4. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457

    Google Scholar 

  5. Lee E (1980) Identification of risk factor related dichotomous data. In: (eds) Statistical methods for survival data analysis. Lifetime Learning, California, p 338

    Google Scholar 

  6. Schwartz S, Yagoda A, Natale RB, Watson RC, Whitmore WF, Lesser M (1983) Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors. J Urol 130: 681

    Google Scholar 

  7. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC, Morse MJ, Whitmore WF (1985) Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133: 403

    Google Scholar 

  8. Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander N, Weiselberg LR, Geller N, Hollander PS, Lipperman R, Fair WR, Whitmore WF Jr (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461

    Google Scholar 

  9. Troner MB, Hemstreet GP III (1981) Cyclophosphamide, doxorubicin and cisplatin (CAP) in the treatment of urothelial malignancy: a pilot study of the Southeastern Cancer Study Group. Cancer Treat Rep 65: 29

    Google Scholar 

  10. World Health Organization (1979) Handbook for reporting results of cancer treatment WHO, Geneva

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Igawa, M., Ohkuchi, T., Ueda, M. et al. Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, Adriamycin, and cisplatin. Cancer Chemother. Pharmacol. 30 (Suppl 1), S77–S80 (1992). https://doi.org/10.1007/BF00686948

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686948

Keywords

Navigation